Abstract
Cellular homeostasis relies on quality control systems so that damaged biologic structures are either repaired or degraded and entirely replaced by newly formed proteins or even organelles. The clearance of dysfunctional cellular structures in long-lived postmitotic cells, like neurons, is essential to eliminate, per example, defective mitochondria, lipofuscin-loaded lysosomes and oxidized proteins. Short-lived proteins are degraded mainly by proteases and proteasomes whether most long-lived proteins and all organelles are digested by autophagy in the lysosomes. Recently, it an interplay was established between the ubiquitin-proteasome system and macroautophagy, so that both degradative mechanisms compensate for each other. In this article we describe each of these clearance systems and their contribution to neuronal quality control. We will highlight some of the findings that provide evidence for the dysfunction of these systems in Alzheimers and Parkinsons diseases. Ultimately, we provide an outline on potential therapeutic interventions based on the modulation of cellular degradative systems.
Keywords: Macroautophagy, proteasome, ubiquitin, protein aggregates, mitochondria, Parkin-mediated mitophagy, neurodegeneration, oxidative stress, Aβ peptide, apoptosis
Current Pharmaceutical Design
Title: Therapeutic Intervention at Cellular Quality Control Systems in Alzheimers and Parkinsons Diseases
Volume: 17 Issue: 31
Author(s): Daniela M. Arduino, A. Raquel Esteves, Diana F.F. Silva, Diogo Martins-Branco, Daniel Santos, Diana F. Gomes Pimentel and Sandra M. Cardoso
Affiliation:
Keywords: Macroautophagy, proteasome, ubiquitin, protein aggregates, mitochondria, Parkin-mediated mitophagy, neurodegeneration, oxidative stress, Aβ peptide, apoptosis
Abstract: Cellular homeostasis relies on quality control systems so that damaged biologic structures are either repaired or degraded and entirely replaced by newly formed proteins or even organelles. The clearance of dysfunctional cellular structures in long-lived postmitotic cells, like neurons, is essential to eliminate, per example, defective mitochondria, lipofuscin-loaded lysosomes and oxidized proteins. Short-lived proteins are degraded mainly by proteases and proteasomes whether most long-lived proteins and all organelles are digested by autophagy in the lysosomes. Recently, it an interplay was established between the ubiquitin-proteasome system and macroautophagy, so that both degradative mechanisms compensate for each other. In this article we describe each of these clearance systems and their contribution to neuronal quality control. We will highlight some of the findings that provide evidence for the dysfunction of these systems in Alzheimers and Parkinsons diseases. Ultimately, we provide an outline on potential therapeutic interventions based on the modulation of cellular degradative systems.
Export Options
About this article
Cite this article as:
M. Arduino Daniela, Raquel Esteves A., F.F. Silva Diana, Martins-Branco Diogo, Santos Daniel, F. Gomes Pimentel Diana and M. Cardoso Sandra, Therapeutic Intervention at Cellular Quality Control Systems in Alzheimers and Parkinsons Diseases, Current Pharmaceutical Design 2011; 17 (31) . https://dx.doi.org/10.2174/138161211798072481
DOI https://dx.doi.org/10.2174/138161211798072481 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanical Design and Control Method for SEA and VSA-based Exoskeleton Devices for Elbow Joint Rehabilitation
Neuroscience and Biomedical Engineering (Discontinued) Therapeutic Effects of Quetiapine on Memory Deficit and Brain β-Amyloid Plaque Pathology in a Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research The Role of the Endocannabinoid System in Eating Disorders: Neurochemical and Behavioural Preclinical Evidence
Current Pharmaceutical Design Benzothiazole: A Versatile and Multitargeted Pharmacophore in the Field of Medicinal Chemistry
Letters in Organic Chemistry Reprogramming of B Cells into Regulatory Cells with Engineered Fusokines
Infectious Disorders - Drug Targets Long-acting Injectable vs. Oral Antipsychotics: Adherence, Persistence and Switching over three Years of Real-life Analysis
Current Reviews in Clinical and Experimental Pharmacology Sialuria-Related Intellectual Disability in Children and Adolescent of Pakistan: Tenth Patient Described has a Novel Mutation in the GNE Gene
CNS & Neurological Disorders - Drug Targets The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases
Current Neuropharmacology Amiodarone - A ‘Broad Spectrum’ Antiarrhythmic Drug
Cardiovascular & Hematological Disorders-Drug Targets ERRATUM
Current Neuropharmacology Quantitative Investigation of Biomolecular Interactions in Crowded Media by Fluorescence Spectroscopy, a Good Choice
Current Protein & Peptide Science Parakeet Hemoglobin – Its Crystal Structure and Oxygen Affinity in Relation to Some Avian Hemoglobins
Protein & Peptide Letters The Evolving Therapy of Rheumatic Diseases, The Future is Now
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Preface [Hot Topic: Cannabinoid Receptors (Guest Editor: Maria L. Lopez-Rodriguez)]
Current Medicinal Chemistry - Central Nervous System Agents Macrophage-Assisted Inflammation and Pharmacological Regulation of the Cholinergic Anti-Inflammatory Pathway
Current Medicinal Chemistry Evidence that Cortical Dopamine is a Co-Transmitter in Noradrenergic Neurons
Current Psychiatry Reviews Atypical Antipsychotic Drugs During Pregnancy. Their Effects on the Mother and Offspring
Current Women`s Health Reviews Therapeutic Utility and Medicinal Chemistry of Cathepsin C Inhibitors
Current Topics in Medicinal Chemistry Mechanisms of Tau Self-Aggregation and Neurotoxicity
Current Alzheimer Research Repetitive Transcranial Magnetic Stimulation Combined with Antidepressants for the First Episode of Major Depressive Disorder
Current Neuropharmacology